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Abstract
Purpose The management of ovarian cancer during
pregnancy is still a big challenge, mostly due to the reci-
procal impacts between cancer and pregnancy. The
objective of this article is to present a rare case of maternal
ovarian adenocarcinoma and review published similar
cases about this clinical condition.
Materials and methods Here we report a rare case of
maternal ovarian adenocarcinoma detected during gesta-
tional week 6, with good pregnancy outcome treated with
conservative surgery.
Results and discussion A case of maternal ovarian ade-
nocarcinoma (stage I) was detected in week 6 of pregnancy
receiving conservative surgery without chemotherapy. In
week 39 of pregnancy, due to relapse of the cancer, the
patient underwent excision of the isolated tumor, and gave
birth to a healthy baby through cesarian section. After that,
the patient received cytoreductive surgery associated with
six chemotherapy. The patient was finally diagnosed as
epithelial ovarian cancer stage IIIC, and had survived more
than 5 years without relapse. The successful experience
from this case suggested that pregnancy complicated with
early ovarian cancer receiving conservative surgery could
continue to pregnancy and the effect of cesarian section
followed with cytoreductive surgery associated with six
chemotherapy at full term was still satisfied.
Keywords Pregnancy  Ovarian cancer  Cytoreductive
surgery  Chemotherapy
Introduction
Ovarian cancer is the second most frequent gynecological
cancer diagnosed during pregnancy, exceeded only by
cervical carcinoma. Even so, ovarian cancer during preg-
nancy is rare, with an estimated incidence of 1:10,000 to
1:50,000 [1–3]. Among all the malignant ovarian tumors
diagnosed during pregnancy, the germ cell tumor is
reportedly the most prevalent, and epithelial ovarian cancer
accounts for 20 % of all ovarian cancers [4–6]. Epithelial
ovarian cancer affects predominantly perimenopausal and
postmenopausal women. Ovarian adenocarcinoma, a sub-
type of epithelial ovarian cancer, is rarely detected during
pregnancy in young women. The frequency of maternal
epithelial ovarian cancer is likely to increase because of the
increasing number of women who postpone childbearing
[3, 5].
The clinical outcome of patients with epithelial ovarian
cancer is not affected by pregnancy. The same surgical
staging procedures are recommended for patients with or
without pregnancy [2–4]. This cancer remains a significant
clinical challenge, however, because ovarian carcinoma
and the treatment for it during pregnancy affect not only
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the pregnant woman but also the fetus [4–6]. Although
cases have been reported anecdotally, there have been no
large-scale randomized trials or cohort studies because of
the low incidence of ovarian cancer during pregnancy
[4–6]. Case reports, however, provide important informa-
tion on the management of these cancers [5]. We report a
case of maternal ovarian adenocarcinoma detected during
gestational week 6. The patient was treated with conser-
vative surgery, without chemotherapy, and gave birth to a
healthy baby during week 39 of the pregnancy.
Case report
Prior written consent of the patient for the use of these
clinical materials for research purposes, and approval from
the Institutional Ethical Board (IRB) in the First Affiliated
Hospital of Sun Yat-sen University were obtained. The
patient was a 25-year-old woman who underwent abdom-
inal ultrasonography (US) because of severe low quadrant
pain that had lasted for 12 h during gestational week 6. The
US showed a cystic solid mass measuring 9 9 6 cm with a
small amount of blood from the left adnexa. No ascites was
found. An emergent laparotomy was performed with a
suspicion of mass torsion. Five serum tumor markers were
measured preoperatively: a-fetoprotein (AFP), cancer
antigen (CA)199, carcinoembryonic antigen (CEA),
CA153, and CA125. CA125 was found to be abnormally
elevated to 121 U/ml.
Laparotomy confirmed the presence of a left ovarian
cyst with a maximum diameter of 9 cm and one round of
torsion. It had a smooth, black surface without excres-
cences, and its section had no papillary proliferations. A
right ovarian complex mass of 3 9 2 cm was also found.
The left mass was managed by unilateral salpingo-oopho-
rectomy. The right mass was removed by cystectomy. Both
masses were completely removed, leaving an intact mem-
brane. No ascitic fluid was found in the abdominal cavity
during the procedure. The omentum, liver, and spleen were
normal. No intraoperative peritoneal implant or suspicious
areas for malignancy were found; so multiple peritoneal
biopsies for surgical staging was not given. Peritoneal
washing during her emergency laparotomy and intraoper-
ative frozen section was not performed. The reason is that
the junior doctors in emergency surgery believed the
twisted mass was benign because the gross mass surface
has no excrescences and was smooth. Another reason is
that nodular necrotic vascular mass section has no papillary
proliferations.
Histological analysis of the left mass showed solid and
cystic areas with regions of hemorrhage and necrosis
(Fig. 1a-c). It confirmed the diagnosis of mucinous cyst-
adenocarcinoma grade I with intact membrane (Fig. 1d).
The right mass was filled with grease and hair, and was
diagnosed as a mature teratoma. Serum tumor markers
including AFP, CA199, CEA, CA153, and CA125 were
measured on postoperative day (POD) 3. The maternal
serum CA125 had dropped from 121 U/ml preoperatively
to 93 U/ml, but the other markers showed no obvious
changes.
After extensive counseling by gynecological oncologists
and pediatricians, the patient expressed a strong desire to
continue the pregnancy and refused another operation for
staging and decisions about chemotherapy. The patient left
the hospital on POD 7 with a diagnosis of International
Federation of Gynecologists and Obstetricians (FIGO)
stage IA carcinoma (at least).
The patient presented again at 39?1 weeks of gestation
with abdominal bloating and dyspepsia that had been
present for about 7 days. US identified a normal fetus in the
uterus. A complex mass measuring 12 9 11 cm and rich
with blood was found between the bladder and uterus. It
appeared to be predominantly cystic although there were
some solid parts and papillary areas. These features sug-
gested relapse of the ovarian adenocarcinoma. The mater-
nal serum CA125 and AFP levels were elevated to 381 U/
ml and 3,810 ng/ml, respectively.
The patient underwent excision of the isolated tumor
with cesarean section at 39?1 weeks of gestation. Cytore-
ductive surgery was then performed, including total
hysterectomy, right salpingo-oophorectomy, complete
omentectomy, and pelvic and para-aortic lymph node
resection.
The baby weighed 3,000 g and had an Apgar score of 10
at 1 min and a score of 10 at 5 min. US examinations of
the baby at 1 month showed normal brain, liver, spleen and
kidneys.
Histopathological diagnosis of the tumor confirmed
isolated metastatic ovarian cystadenocarcinoma. The
lymph nodes, uterus, right adnexa, omentectomy and pla-
centa were negative for metastasis (Fig. 2). The patient
received six courses of cisplatinum 75 mg/m2 and doce-
taxel 75 mg/m2 every 4 weeks after surgery. The AFP and
CA125 levels were normal on POD 28 and after the third
cycle of chemotherapy, respectively. The patient and her
baby were followed up for more than 5 years, during which
time the serum AFP and CA125 assays and abdominal US
scan showed no evidence of tumor recurrence in the
woman. The baby had normal physical and neurological
development.
Discussion
The incidence of pregnancy complicated by ovarian cancer
is low. Among the ovarian cancers reported in one study,
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47.8 % were malignant germ cell tumors, 21.7 % were
borderline malignant tumors, 17.4 % were invasive epi-
thelial tumors, and 13.1 % were sex cord stromal tumors
[4]. In all, 73.9 % of those patients were diagnosed in stage
I disease and had complete remissions [4]. Another liter-
ature review of 41 cases of maternal epithelial ovarian
cancer reported between 1958 and 2007 revealed that the
mean age of the patients at the first visit was 32.6 years
Fig. 1 The pathological examination of the primary ovarian adeno-
carcinoma from a 25-year-old woman during gestational week 6.
a Histological analysis showed highly differentiated mucinous
cystadenocarcinoma grade I. Atypic glands arranged in dense and
cancer cell with large and deeply stained nuclei arranged in disorder.
HE staining 9400; b local hemorrhage of the ovarian adenocarci-
noma, HE staining 9200; c local necrosis of the ovarian adenocar-
cinoma, HE staining 9400; d the intact membrane can be observed at
the edge of the tumor. HE staining 9400
Fig. 2 The abdominal metastatic ovarian adenocarcinoma at
39 ? 1 weeks of gestation. Histological analysis showed metastatic
moderately differentiated ovarian adenocarcinoma. Atypic glands
were very few or almost none and small tumor cell with mitotic
figures arranged in nests. a HE staining 9200; b HE staining 9400
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(range 23-46 years), with 69 % [30 years, 36 % [35
years, and 28 % [40 years [5].
Primary ovarian carcinoma occurs most commonly in
women of low parity during the latter half of their repro-
ductive years and remains the fifth most common cause of
cancer-related death for women in the United States [5]. A
study showed that of 28,165 patients diagnosed with epi-
thelial ovarian cancer, 400 were \30 years (very young),
11,601 were 30-60 (young), and 16,164 were[60 (older)
years of age. Moreover, very young women usually had a
significant survival advantage over the young and older
groups with 5-year disease-specific survival estimates at
78.8 % versus 58.8 and 35.3 %, respectively [7].We
reported here a 25-year-old woman with ovarian cystade-
nocarcinoma who underwent emergent surgery because of
torsion of a mass during the first trimester. Her case posed
great challenges for the multidisciplinary team responsible
for her care owing to postoperative confirmation of a
malignant tumor without staging and the presence of a first
trimester pregnancy. At this stage, the embryo is sensitive
to chemotherapy including cisplatin, carboplatin, toxtocile,
and bleomycin [8]. It was recommended that she undergo
unilateral adnexectomy if it was a stage IA tumor or
bilateral adnexectomy if it was a stage IB tumor; in the
latter case (grade B), peritoneal cytology and complete
abdominopelvic exploration would be added [9]. The
patient insisted on continuing the pregnancy, and she did
not undergo staging surgery or chemotherapy. If she had
undergone surgery, it would have had adverse effects on
the embryo; and chemotherapy was contraindicated during
the first trimester [4–6].
It has been recommended in previous reports that
pregnant women with ovarian malignancy should be trea-
ted in the same way as nonpregnant women [5, 10], with
similar prognoses for the nonpregnant and pregnant women
at the same cancer stage [5, 9–13]. When considering
surgical intervention during the first trimester, we have to
face the risk of spontaneous miscarriage following lapa-
rotomy. The second trimester is generally regarded as the
best time for surgical intervention because the risk of
miscarriage is lower [10, 11].
In 2009, Palmer et al. [5] reported that since 1968 only
three women had undergone surgery during the first tri-
mester. One of them experienced subsequent termination of
the pregnancy during the second trimester. Although no
adverse event following surgery was reported during the
first trimester, the number was too low to draw a general
conclusion. Our case is therefore a useful contribution to
the treatment of maternal ovarian cancer during the first
trimester.
Nonpregnant patients with stage I ovarian cancer rarely
have recurrence after unilateral salpingo-oophorectomy,
and they have a good prognosis, with 5-year survival rates
[90 % [14–17]. No significant difference in overall out-
come was found between patients with incomplete staging
and those with complete staging [18]. Nonpregnant patients
with advanced ovarian cancer were prone to relapse, with
5-year survival rates \30 % [17–20].
Our patient was the first reported case of a recurrent
tumor 32 weeks after salpingo-oophorectomy at week 6?5
of gestation. Cytoreductive surgery proved that the iso-
lated complex mass located between the bladder and
uterus was metastatic ovarian adenocarcinoma; the other
organs including pelvic and para-aortic lymph nodes were
negative for malignancy. At 47 months after the last
chemotherapy was given, there was no evidence of
recurrence clinically or radiologically. This case was
different from those in previous reports in which patients
with early-stage ovarian cancer were more prone to
relapse but had a better prognosis than nonpregnant
women with late-stage ovarian cancer. The metastatic
tumors were usually disseminated from advanced ovarian
cancers in nonpregnant women. Our case was an isolated
tumor in stage C. It is important to consider the impact of
the cancer on the pregnancy and, conversely, the impact
of the pregnancy on the cancer.
Previous reports noted that tumor markers are of
limited value for substantiating a diagnosis during
pregnancy because the serum CA125 levels may be
elevated in normal pregnancy, usually peaking in the first
trimester and returning to normal range (\65 U/ml) in
the second trimester [5, 21–23]. In our case, the serum
CA125 level was 121 U/ml at an early stage and dropped
to 93 U/ml 3 days after surgery. When the tumor
relapsed, the serum CA125 levels rose to 381 U/ml and
again dropped to normal after cytoreductive surgery
following three cycles of chemotherapy. The fluctuation
of CA125 in this case was similar to that in nonpregnant
women with epithelial ovarian cancer, suggesting that
CA125 may provide some information when screening,
diagnosing, and monitoring some epithelial ovarian
cancers during pregnancy.
In summary, the treatment of epithelial ovarian carci-
noma during pregnancy remains a challenge because of the
paucity of data and the impact on the fetus. It is important
to consider the reciprocal effects on the cancer and the
pregnancy. Intensive follow-up of the patient is necessary
because the tumor is prone to recurrence. More cases need
to be analyzed to obtain a clear picture of the long-term
survival rate.
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